[Effect of paraneoplastic rheumatic syndrome in lung cancer patients on tumor expression of BCL-2].
A qualitative and quantitative immunohistochemical evaluation of expression of oncoprotein Bcl-2 in 140 patients with lung cancer (LC) was performed: 57 patients with paraneoplastic rheumatic syndrome (PNRS) and 83 without symptoms of the syndrome. It was established that in the group of lung cancer patients with manifestations of PNRS the expression of Bcl-2 was rarely observed, and the average level of expression of Bcl-2 was much lower when compared to similar patients with lung cancer but without symptoms of the given syndrome. The presence of PNRS in patients with lung cancer leads to reduced tumor expression by Bcl-2, indicating a higher malignancy and aggressive nature of the tumors.